Back

Cardiovascular related polypharmacy and its association with liver and kidney impairment amongst individuals on lipid-lowering therapy: a cross-sectional study using primary care data

31 August 2024 (16:00 - 16:50)
Organised by: Logo
Congress Presentation Part of: Lipid-lowering therapy: statins and beyond Cardiovascular Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Assistant Professor Stella Talic

Monash University, Melbourne (Australia)

6 More presentations in this session

Presentation thumbnail
Plasma statin concentrations do not correlate with statin-induced myalgia
Doctor M. Ritvos (Helsinki, FI)
Abstract Slides Video
Presentation thumbnail
The high-dose statin treatment reduces neutrophil extracellular traps formation in patients with coronary artery disease
Doctor K. Stepien (Krakow, PL)
Abstract Slides Video
Presentation thumbnail
Long-term administration of atorvastatin had no effect on the occurrence and progression of spontaneous hypertensive intracerebral hemorrhage in mice
Doctor X. Bian (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of inclisiran in real-world clinical practice. Results from the CHOLINET Registry
Doctor F. Marzano (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Impact of allogenic Fecal Microbiota Transplantation (FMT) on lipid parameters in patients with metabolic syndrome (MetS): a meta-analysis
Doctor L. Wang (Beijing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Lipid-lowering therapy: statins and beyond

The Event

Event poster

ESC Congress 2024

31 August 2024 16:00 CET
You may be interested in
thumbnail
Congress Presentation
Impact of polypharmacy phenogroups on different heart failure phenotypes in patients with chronic heart failure (polypharmacy phenogroups and heart failure subgroups outcomes)
31 August 2025
thumbnail
Congress Presentation
Cardiovascular-kidney-liver-metabolic-health:a population-based study on the prognostic impact of the coexistence of metabolic dysfunction-associated steatotic liver disease and chronic kidney disease
30 August 2025
thumbnail
Congress Presentation
Temporal trends in lipid-lowering therapy utilization among ASCVD patients: a large-scale database analysis
29 August 2025
thumbnail
Congress Presentation
Dangers of polypharmacy: how to identify and how to limit the risk
4 April 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources